Compare Northrop Grumman Corporation (NOC) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Northrop Grumman Corporation vs Travere Therapeutics Inc. Common Stock — how do they compare? Northrop Grumman Corporation trades at $497.31 (market cap $68.39B), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B). The key difference: Northrop Grumman Corporation is far larger — about 14× Travere Therapeutics Inc. Common Stock's market cap, and Northrop Grumman Corporation pays a 2.05% dividend while Travere Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Northrop Grumman Corporation for 82 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| NOC | TVTX | |
|---|---|---|
Market Cap | $68.39B | $4.88B |
Volume | 823,323 | 1,668,577 |
Sector | Industrials | Health |
52-Week High | $768.02 | $67.52 |
52-Week Low | $473.46 | $26.79 |
Typical Hold Time | 82 Days | 0 Days |
Enterprise Value | $82.37B | $5.01B |
Dividend Yield | 2.05% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Northrop Grumman (NOC) trades at $495.69, up 2.2% on the day, amid a bearish technical signal but strong fundamentals. The company has beaten earnings estimates for the last three quarters, with a net income margin of 10.48% and a P/E ratio of 15.3. Recent news highlights a $20 billion Navy fighter contract loss to Boeing, though the company maintains a record backlog and a dividend payout.
The outlook is mixed: analyst consensus is bullish with a $595.69 price target, but technical indicators and recent contract loss pose near-term risks. Long-term growth is supported by defense spending and key programs like the B-21 bomber, though competitive pressures and execution risks remain.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Northrop Grumman Corporation
Northrop Grumman is a defense contractor that is diversified across short-cycle and long-cycle businesses. The firm's segments include aeronautics, mission systems, defense services, and space systems. The company's aerospace segment creates the fuselage for the massive F-35 program and produces various piloted and autonomous flight systems. Mission systems creates a variety of sensors and processors for defense hardware. The defense systems segment is a long-range missile manufacturer. Finally, the company's space systems segment produces various space structures, sensors, and satellites.
Read more on NOC →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
